Open AccessImlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes)
Author(s) -
Stanley C. Jordan,
Christophe Legendre,
Niraj M. Desai,
Tomas Lorant,
Mats Bengtsson,
Bonnie E. Lonze,
Ashley Vo,
Anna Runström,
Lena Laxmyr,
Kristoffer Sjöholm,
Åsa Schiött,
Elisabeth Sonesson,
Kathryn J. Wood,
Lena Winstedt,
Christian Kjellman,
Robert A. Montgomery
Publication year - 2021
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0000000000003496
Subject(s) - medicine , adverse effect , desensitization (medicine) , immunogenicity , antibody , panel reactive antibody , kidney transplantation , gastroenterology , renal function , transplantation , immunology , dialysis , urology , receptor
Highly HLA sensitized patients have limited access to life-saving kidney transplantation because of a paucity of immunologically suitable donors. Imlifidase is a cysteine protease that cleaves IgG leading to a rapid decrease in antibody level and inhibition of IgG-mediated injury. This study investigates the efficacy and safety of imlifidase in converting a positive crossmatch test to negative, allowing highly sensitized patients to be transplanted with a living or deceased donor kidney.